The current EADV guidelines for the management of pemphigus recommend maintenance treatment with rituximab administered 6 months after the initial cycle in doses ranging from 500 mg to 1 g in patients who achieved complete remission, especially patients with severe PV at initial presentation and/or patients with high anti-Dsg antibodies levels at month 3 and a full cycle (two infusions of 1 g two weeks apart) in patients without complete remission. Here, DSG1 is linked to pemphigus.